EG-1962
As of the edition of 20 October 2026, EG-1962 is a drug known only by a code name: stopped in 2018; acts on CACNA1C, CACNA1D and CACNA1F and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Code name only
- Registered trials
- 2, 2 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product5 company-target rows are on route A because of EG-1962.
See the 5 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CACNA1F | Voltage-dependent L-type calcium channel subunit alpha-1F | O60840 |
| NR3C2 | Mineralocorticoid receptor | P08235 |
| CACNA1D | Voltage-dependent L-type calcium channel subunit alpha-1D | Q01668 |
| CACNA1S | Voltage-dependent L-type calcium channel subunit alpha-1S | Q13698 |
| CACNA1C | Voltage-dependent L-type calcium channel subunit alpha-1C | Q13936 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Edge Therapeutics | Lead sponsor of trials | 2016 to now |